"APA and ISPOR are two of the most important meetings of the year for mental health experts and health economics leaders to engage in scientific exchange," said
Highlights of the upcoming presentations at APA include a poster reviewing antipsychotic efficacy results from three double-blind, olanzapine-controlled randomized clinical studies of ALKS 3831 (olanzapine/samidorphan), as well as posters relating to addiction and major depressive disorder. At ISPOR,
"There is increasing recognition in the healthcare community and society at large of the tremendous toll that mental health disorders place on all layers of the healthcare ecosystem, from individual patients, to caregivers, providers and insurers," said
Presentations at the APA Annual Meeting will include:
Schizophrenia
- Poster #P6-090: "Antipsychotic Efficacy of a Combination of Olanzapine and Samidorphan Across Three Olanzapine-Controlled Clinical Studies," will be presented by
Adam Simmons ,Alkermes, Inc. , onMonday, May 20, 2019 , 2:00 –4:00 p.m. PT
- Poster #P7-063: "A Combination of Olanzapine and Samidorphan Mitigates Weight Gain Observed With Olanzapine: Results From the Phase 3 ENLIGHTEN-2 Schizophrenia Study," will be presented by
Christoph Correll , M.D., Psychiatry and Molecular Medicine atHofstra Northwell School of Medicine , onTuesday, May 21 ,10:00 a.m. –12:00 p.m. PT
Alcohol and Opioid Use Disorder
- Poster #P6-032: "Transition From Buprenorphine Maintenance to Extended-Release Naltrexone: Hybrid Residential-Outpatient Randomized Controlled Trial," will be presented by
Paolo Mannelli , M.D.,Duke University School of Medicine , onMonday, May 20, 2019 , 2:00 –4:00 p.m. PT
- Poster #P6-034: "Opioid Overdose in Patients Treated With Extended-Release Naltrexone: Postmarketing Data From 2006 to 2018," will be presented by
Kimberley Marcopul ,Alkermes, Inc. , onMonday, May 20, 2019 , 2:00 –4:00 p.m. PT
Major Depressive Disorder
- Poster #P6-092: "Long-Term Treatment With Adjunctive Buprenorphine/Samidorphan Combination in Patients With Major Depressive Disorder: Phase 3 Study Results," will be presented by
Michael E. Thase , M.D.,Perelman School of Medicine at theUniversity of Pennsylvania , onMonday, May 20, 2019 , 2:00 –4:00 p.m. PT
- Poster #P6-094: "Evaluating the Safety of Buprenorphine/Samidorphan for Adjunctive Treatment of Major Depressive Disorder: A Focus on Buprenorphine-Related Concerns," will be presented by
Andrew Cutler , M.D.,Meridien Research , onMonday, May 20, 2019 , 2:00 –4:00 p.m. PT
- Poster #P6-095: "The Safety of Buprenorphine/Samidorphan Combination as Adjunctive Therapy for Major Depressive Disorder: A Pooled Analysis of 4 Clinical Trials," will be presented by
Andrew Cutler , M.D.,Meridien Research , onMonday, May 20, 2019 , 2:00 –4:00 p.m. PT
Presentations at ISPOR 2019 will include:
- Podium Presentation, "Treatment Experiences of Patients With Schizophrenia: Findings From a Qualitative Focus Group Study," will be presented by
Leona Bessonova , Ph.D.,Alkermes, Inc. , onMonday, May 20, 2019 , 5:00 –6:00 p.m. CT
- Poster PMH21, "The Economic Burden of Illness of Schizophrenia in the U.S.," will be presented by
Leona Bessonova , Ph.D.,Alkermes, Inc. , onMonday, May 20, 2019 , 3:30 –7:00 p.m. CT
- Poster PMH64, "Treatment Experiences of Patients With Bipolar I Disorder: A Qualitative Focus Group Study," will be presented by
Amy O'Sullivan , Ph.D.,Alkermes, Inc. , onMonday, May 20, 2019 , 3:30 –7:00 p.m. CT
- Poster PMH20, "The Economic Burden of Bipolar Disorder in
the United States : Results From a Systematic Literature Review," will be presented byLeona Bessonova , Ph.D.,Alkermes, Inc. , onMonday, May 20, 2019 , 3:30 –7:00 p.m. CT
Visit the APA and ISPOR annual meeting websites for a list of all presentations taking place at each conference.
About ALKS 3831
ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia. ALKS 3831 is composed of samidorphan, a novel, new molecular entity, co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
About ALKS 5461
ALKS 5461 is a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist. ALKS 5461 is a proprietary, investigational, once-daily oral medicine that acts as an opioid system modulator and is being studied for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies.
About Alkermes
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the potential therapeutic value of the company's approved products and investigational product candidates and the company's plan for presentations of results from studies of its approved products and investigational product candidates. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include those risks described in the
Alkermes Contacts:
For Investors: |
Sandy Coombs |
+1 781 609 6377 |
For Media: |
Marisa Borgasano |
+1 781 609 6659 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-to-showcase-leadership-in-schizophrenia-with-new-data-presentations-at-upcoming-scientific-conferences-300848393.html
SOURCE